American journal of ophthalmology case reports · 2022
Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El Wardani Mohamad, de Smet Marc D
Аннотация
PURPOSE: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use.
OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable.
CONCLUSIONS AND IMPORTANCE: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery.
OBSERVATIONS: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable.
CONCLUSIONS AND IMPORTANCE: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery.